Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Ann Neurol
    October 2026
  1. ABOSEIF A, Cacciaguerra L, Vilaseca A, Kondrakunta S, et al
    Selective Limbic and Striatal Atrophy Corresponds to Regional Gene Expression in Leucine-Rich Glioma-Inactivated-1 Immunoglobulin G Autoimmune Encephalitis.
    Ann Neurol. 2026 Oct 6. doi: 10.1002/ana.78389.
    >> Share

  2. AHOLA V, Saraste M, Pedrini E, Tuomaala J, et al
    Serum Chitotriosidase Links to Activated Glia at Chronic Active Lesion Rims in Multiple Sclerosis Brain.
    Ann Neurol. 2026 Oct 6. doi: 10.1002/ana.78386.
    >> Share

    September 2026
  3. MONTINI F, Pittock SJ, Cacciaguerra L, Weiner HL, et al
    Reframing the Gut-Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases.
    Ann Neurol. 2026 Sep 26. doi: 10.1002/ana.78380.
    >> Share

  4. JACOBS BM, Tregaskis-Daniels E, Schalk L, Nagrodski J, et al
    Association Between Genetic Ancestry and Multiple Sclerosis Severity.
    Ann Neurol. 2026 Sep 25. doi: 10.1002/ana.78350.
    >> Share

  5. HAN S, Liang Z, Zhang C, Yang S, et al
    The IL-1beta-STING Signaling Axis Drives Neuromyelitis Optica Pathogenesis in a Murine Model.
    Ann Neurol. 2026;100:487-510.
    >> Share

    July 2026
  6. AMEZCUA L, Reder AT, Bernitsas E, Monson NL, et al
    Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.
    Ann Neurol. 2026 Jul 30. doi: 10.1002/ana.78290.
    >> Share

  7. BRENNER J, Crijnen YS, Kulderij I, Olijslagers SHC, et al
    A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE.
    Ann Neurol. 2026 Jul 6. doi: 10.1002/ana.78287.
    >> Share

  8. REINDERS EM, Masot-Llima A, Otero-Romero S, Carvajal R, et al
    Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.
    Ann Neurol. 2026 Jul 6. doi: 10.1002/ana.78275.
    >> Share

  9. WU T, Jiang Y, Lin J, Zhang J, et al
    AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.
    Ann Neurol. 2026 Jul 3. doi: 10.1002/ana.78297.
    >> Share

    June 2026
  10. PIRRONELLO M, Picozza M, Guerrera G, Corbisiero S, et al
    From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis.
    Ann Neurol. 2026 Jun 18. doi: 10.1002/ana.78277.
    >> Share

  11. FRISELL T, Hedberg S, Piehl F
    Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.
    Ann Neurol. 2026 Jun 17. doi: 10.1002/ana.78286.
    >> Share

  12. BEHRENS M, Terroba-Navajas P, Willemse EAJ, Schadelin S, et al
    Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2026 Jun 17. doi: 10.1002/ana.78285.
    >> Share

  13. PANTULIANO MC, Arlt FA, Arenson N, Basuroski ID, et al
    Gephyrin Neurological Autoimmunity.
    Ann Neurol. 2026 Jun 17. doi: 10.1002/ana.78278.
    >> Share

  14. MARMOLEJO L, Papi C, Milano C, Aguilar E, et al
    CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.
    Ann Neurol. 2026;99:1468-1479.
    >> Share

    May 2026
  15. DING Y, Hamitouche D, Thebault S, Kearns P, et al
    Genetic-Proteomic Integration Identifies Predictive Plasma Proteins for Multiple Sclerosis.
    Ann Neurol. 2026 May 22. doi: 10.1002/ana.78256.
    >> Share

  16. SCHNEIDER-HOHENDORF T, Eveslage M, Wirth T, Wunsch C, et al
    Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.
    Ann Neurol. 2026;99:1166-1172.
    >> Share

  17. PU YL, Feng JZ, Meng HX, Xiao HB, et al
    Myelitis-Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late-Onset Neuromyelitis Optica Spectrum Disorders.
    Ann Neurol. 2026;99:1139-1151.
    >> Share

    April 2026
  18. GERNERT JA, Bartos LM, Christmann T, Zausinger H, et al
    Hyperreflective Foci in the Inner Nuclear Layer: Proof-of-Concept for an Optical Coherence Tomography Derived Microglia-Related Marker in Multiple Sclerosis.
    Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78215.
    >> Share

  19. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
    Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
    Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78222.
    >> Share

  20. COPELAND TP
    Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
    Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78218.
    >> Share

    March 2026
  21. WANG Y, Gao X, Kokubun N, Shan F, et al
    Gelsolin-3: A Novel Myelin Autoantigen in Demyelinating Guillain-Barre Syndrome.
    Ann Neurol. 2026 Mar 24. doi: 10.1002/ana.78198.
    >> Share

  22. THAKOLWIBOON S, Wood KN, Stabile A, Paramasivan N, et al
    Population-Based Epidemiology of Autoimmune Seizures and Epilepsies.
    Ann Neurol. 2026 Mar 24. doi: 10.1002/ana.78204.
    >> Share

    February 2026
  23. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
    Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
    Ann Neurol. 2026;99:553.
    >> Share

    January 2026
  24. BOURDETTE D, Silbermann E
    Stop the Spin: Confronting Reporting Bias in Multiple Sclerosis Research.
    Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78126.
    >> Share

  25. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Candal-Pedreira C, Garcia G, et al
    Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials.
    Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78125.
    >> Share

  26. PISA M, Lockhart A, Angell T, Avery A, et al
    Topographical Variation of Iron-Rimmed Lesions in the Multiple Sclerosis Brain and Spinal Cord: A Neuropathological Study.
    Ann Neurol. 2026 Jan 18. doi: 10.1002/ana.78113.
    >> Share

  27. SMITH C, Greenberg BM, Reynolds J, Mosavi-Hecht R, et al
    A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis.
    Ann Neurol. 2026 Jan 10. doi: 10.1002/ana.78149.
    >> Share

  28. CORSTEN CEA, Marques AM, Vinke EJ, de Mol CL, et al
    Brain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis.
    Ann Neurol. 2026 Jan 5. doi: 10.1002/ana.78148.
    >> Share

    December 2025
  29. SABATINO JJ JR, Cree BAC, Hauser SL
    Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".
    Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78124.
    >> Share

  30. BIRNBAUM G
    New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
    Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78121.
    >> Share

  31. WAEDE M, Kingo C, Damsbo K, Joergensen MU, et al
    Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy.
    Ann Neurol. 2025;98:1283-1298.
    >> Share

    November 2025
  32. CHEN J, Su C, Feng L, Wang H, et al
    Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.
    Ann Neurol. 2025 Nov 24. doi: 10.1002/ana.78093.
    >> Share

  33. LOREFICE L, Pellecchia MT
    Frailty across Neurological Diseases: Why Sex and Gender Matter.
    Ann Neurol. 2025 Nov 21. doi: 10.1002/ana.78110.
    >> Share

  34. ABRAMS AW, Waltz M, Casper TC, Aaen G, et al
    Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.
    Ann Neurol. 2025 Nov 6. doi: 10.1002/ana.78086.
    >> Share

    October 2025
  35. SIMPSON-YAP S, Morwitch E, Tanner SA, Thomson SM, et al
    Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset.
    Ann Neurol. 2025 Oct 10. doi: 10.1002/ana.78043.
    >> Share

  36. GHEZZI L, Kosa P, Greenwood M, Alvarez E, et al
    From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.
    Ann Neurol. 2025 Oct 3. doi: 10.1002/ana.78047.
    >> Share

  37. FISSE AL, Bonberg N, Beuker C, Pfeuffer C, et al
    Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System-A Multicenter Cohort Study in 163 Patients.
    Ann Neurol. 2025;98:883-893.
    >> Share

    September 2025
  38. BREVILLE G, Benkhoucha M, Rezk A, Tran NL, et al
    Pro-Inflammatory c-Met(+) CD4 T Cells in Multiple Sclerosis.
    Ann Neurol. 2025 Sep 26. doi: 10.1002/ana.78035.
    >> Share

  39. SIAVOSHI F, Smith MD, Cassard S, Moreau GB, et al
    Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.
    Ann Neurol. 2025 Sep 19. doi: 10.1002/ana.78044.
    >> Share

  40. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
    Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
    Ann Neurol. 2025 Sep 8. doi: 10.1002/ana.78033.
    >> Share

  41. ROY B, Chen J, Khani-Habibabadi F, McLaren N, et al
    A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.
    Ann Neurol. 2025 Sep 6. doi: 10.1002/ana.78017.
    >> Share

    August 2025
  42. MANOUCHEHRINIA A, Fitzgerald KC, Salter A, Marrie RA, et al
    Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2025 Aug 7. doi: 10.1002/ana.70020.
    >> Share

    July 2025
  43. KUNCHOK A, Amin M, Ongphichetmetha T, Du M, et al
    Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations.
    Ann Neurol. 2025 Jul 29. doi: 10.1002/ana.27309.
    >> Share

  44. CREE BAC, Freedman MS, Gold M, Pfleeger K, et al
    Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
    Ann Neurol. 2025 Jul 23. doi: 10.1002/ana.27262.
    >> Share

    June 2025
  45. SACCO S, Papinutto N, Schoeps VA, Cheng S, et al
    High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
    Ann Neurol. 2025 Jun 24. doi: 10.1002/ana.27298.
    >> Share

  46. DISANTO G, Sacco R, Mallucci G, Zecca C, et al
    Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
    Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
    >> Share

  47. SABATINO JJ JR, Cree BAC, Hauser SL
    New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
    Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270.
    >> Share

    April 2025
  48. POOLE S, Sisodia N, Koshal K, Henderson K, et al
    Detecting New Lesions Using a Large Language Model: Applications in Real-World Multiple Sclerosis Datasets.
    Ann Neurol. 2025 Apr 25. doi: 10.1002/ana.27251.
    >> Share

  49. MURARO PA, Zito A, Signori A, Sormani MP, et al
    Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
    Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247.
    >> Share

  50. PANSIERI J, Pisa M, Yee S, Gutnikova A, et al
    Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex.
    Ann Neurol. 2025 Apr 8. doi: 10.1002/ana.27231.
    >> Share

    February 2025
  51. GUO K, Peng F, Liu J, Long Y, et al
    Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
    Ann Neurol. 2025 Feb 24. doi: 10.1002/ana.27218.
    >> Share

  52. ABBADESSA G, Nagano A, Hametner S, Howell O, et al
    Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics.
    Ann Neurol. 2025 Feb 14. doi: 10.1002/ana.27216.
    >> Share

  53. HASHEMI E, Srivastava IN, Aguirre A, Yoseph ET, et al
    A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets.
    Ann Neurol. 2025;97:296-312.
    >> Share

  54. PAPADOPOULOS D, Magliozzi R, Bandiera S, Cimignolo I, et al
    Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.
    Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195.
    >> Share

    January 2025
  55. MARGONI M, Storelli L, Pagani E, Preziosa P, et al
    Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.
    Ann Neurol. 2025 Jan 18. doi: 10.1002/ana.27180.
    >> Share

    December 2024
  56. BRIER MR, Judge B, Ying C, Salter A, et al
    Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
    Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165.
    >> Share

  57. HELBIG I, Ganesan S
    NORSE, FIRES, and a Polygenic Trickle of Autoimmunity.
    Ann Neurol. 2024 Dec 7. doi: 10.1002/ana.27148.
    >> Share

    November 2024
  58. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
    Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
    Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
    >> Share

  59. CABALLERO-AVILA M, Martin-Aguilar L, Pascual-Goni E, Michael MR, et al
    Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
    Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142.
    >> Share

  60. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
    Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
    Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
    >> Share

  61. MEUTH SG, Wolff S, Muck A, Willison A, et al
    Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
    Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
    >> Share

    October 2024
  62. WANG W, Yin J
    Coexistence of Acute Cerebral Infarction and Reversible Posterior Encephalopathy Syndrome in a Patient with Hashimoto's Thyroiditis.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27120.
    >> Share

  63. JANG Y, Hong SE, Ahn SH, Mon SY, et al
    Polygenic Landscape of Cryptogenic New-Onset Refractory Status Epilepticus: A Comprehensive Whole-Genome Sequencing Study.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27100.
    >> Share

  64. ALZAMANAN F, Ding Y, Harroud A
    Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
    Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
    >> Share

  65. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
    RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
    >> Share

  66. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
    Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
    >> Share

  67. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
    Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
    >> Share

  68. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
    Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
    Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
    >> Share

  69. SUZUKI S, Utsugisawa K
    MuSK-Myasthenia Gravis and Cancer.
    Ann Neurol. 2024 Oct 8. doi: 10.1002/ana.27094.
    >> Share

  70. FALSO S, Iorio R
    Reply to "MuSK-Myasthenia Gravis and Cancer".
    Ann Neurol. 2024 Oct 4. doi: 10.1002/ana.27091.
    >> Share

    September 2024
  71. FADDA G, Banwell B, Elliott C, Fetco D, et al
    Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
    Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
    >> Share

    August 2024
  72. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    >> Share

    July 2024
  73. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    >> Share

  74. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    >> Share

  75. FALSO S, Gessi M, Marini S, Benvenuto R, et al
    Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.
    Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033.
    >> Share

  76. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    >> Share

  77. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    >> Share

  78. GUO A, Zhang Z, Dong GH, Su L, et al
    Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2024;96:194-203.
    >> Share

    June 2024
  79. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    >> Share

    May 2024
  80. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    >> Share

  81. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    >> Share

    April 2024
  82. GILLIGAN M, Lesnick CE, Guo Y, Bradshaw MJ, et al
    Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis.
    Ann Neurol. 2024 Apr 18. doi: 10.1002/ana.26943.
    >> Share

  83. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    >> Share

    March 2024
  84. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    >> Share

  85. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    >> Share

  86. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    >> Share

    February 2024
  87. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    >> Share

  88. SHU Y, Huang R, Li Q, Lu Y, et al
    Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with HLA-A*3303 and HLA-DPB1*0501.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899.
    >> Share

  89. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    >> Share

    December 2023
  90. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    >> Share

  91. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    >> Share

  92. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    >> Share

  93. DUCHOW A, Bellmann-Strobl J, Friede T, Aktas O, et al
    Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26858.
    >> Share

  94. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    >> Share

  95. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    >> Share

    November 2023
  96. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    >> Share

    October 2023
  97. MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al
    Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
    Ann Neurol. 2023;94:727-735.
    >> Share

    September 2023
  98. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    >> Share

  99. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016